This large sector covers the production and sale of consumer goods, as well as various consumer services including electronic commerce and health care. Since 1996, Baring Vostok funds have invested over $400 million in 13 companies from this sector.
Location:
Saint Petersburg, Russia
Years:
2016
Shareholding:
Minority stake

Solopharm is a producer of pharmaceuticals, with focus on liquid drugs production. Product portfolio of Solopharm includes infusions, injectables, and a number of emerging branded products — ophthalmological drugs, nasal forms. All the drugs are generic drugs. Products are sold both to Russian hospitals and to pharmacies. The Company operates modern production facility located in Saint-Petersburg.

Other projects

News

04 September 2012

The OZON Group has today announced financial results for its second quarter ended June 30, 2012.

The company’s growth rate is reported at 78% in USD, up to $232M, and 91%* in Rubles, up to 7.1B Rubles.

"After coming off of a benchmark year for The OZON Group, 2012 began with the pivotal acquisition of Sapato.ru which has strengthened the already fortified leadership of OZON in the marketplace," said Maelle Gavet, CEO of OZON Holdings. "Efforts for the past six months have been concentrated on furthering the growth of OZON as a whole while blending Sapato.ru and OZON.ru to band together seamlessly. It has been a very organic and prolific progression."

02 May 2012

AVITO.ru closes $ 75 million fund-raising from Accel Partners and Baring Vostok Private Equity Fund IV to accelerate Russian expansion.

<p>AVITO.ru, the largest online classifieds website in Russia, announced today that it has received $75 million in new funding from Baring Vostok Private Equity Fund IV, Accel Partners, and existing investors Kinnevik and Northzone. The new funds will be used to further fuel the company’s strong growth throughout Russia and to continue attracting world-class talent.</p>